Recently, the combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib was approved by FDA to treat patients harboring BRAF (V600E) mutation in NSCLC (non-small cell lung cancer) or melanoma. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.